Aprea Therapeutics Receives Nasdaq Extension to Meet $1 Bid Rule

What Happened
Aprea Therapeutics, Inc. (APRE) filed an 8-K on July 23, 2026 (Item 3.01) reporting that Nasdaq has granted the company an additional 180-calendar-day compliance period to meet the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market. The new deadline (the “Second Compliance Period”) runs through January 19, 2027. The company previously received a deficiency notice on January 23, 2026 and was initially given until July 22, 2026 to regain compliance.

Key Details

• Nasdaq extended the compliance period by 180 calendar days, through January 19, 2027.
• To cure the deficiency, APRE must have a closing bid of at least $1.00 per share for a minimum of 10 consecutive business days.
• If APRE does not demonstrate compliance by January 19, 2027, Nasdaq will notify the company that its common stock will be delisted; the company can appeal to a Nasdaq hearings panel.
• The filing was made on July 23, 2026 under Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard).

Why It Matters
This notice signals a continued risk that APRE’s shares could be removed from Nasdaq if the stock does not trade back at or above $1.00 for the required period. Delisting can reduce liquidity, limit where and how investors can trade the shares, and may affect institutional ownership and broker-dealer support. Investors should monitor the company’s closing bid price, company updates, and any appeal or remediation steps Aprea may announce.